V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004130 | 310001766 | null | null | null | 2017-05-08 | 2017-05-09 | Rituximab | 02 | N | 310019287 | BEXAROTENE |
| 310004131 | 310006765 | 1.73 | 84.7 | Neo-adjuvant (N) | 2014-07-29 | 2014-08-06 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | Y | 310019288 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004132 | 310001767 | 0 | 58 | Palliative (P) | 2013-10-29 | 2013-10-29 | Imatinib 400mg | N | N | 310019289 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004133 | 310001768 | 1.63 | null | Disease modification (D) | 2017-12-24 | 2017-12-24 | Oxaliplatin + Modified de Gramont | 02 | N | 310019293 | GEMCITABINE + PACLITAXEL |
| 310004134 | 310001768 | 1.6 | null | Neo-adjuvant (N) | 2016-01-09 | 2016-01-09 | Bevacizumab+Carbo+Pacliaxel | null | Y | 310019293 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004135 | 310001768 | 1.7 | 82 | Palliative (P) | 2016-03-24 | 2016-04-09 | CAPECITABINE + OXALIPLATIN | N | N | 310019293 | IMATINIB |
| 310004136 | 310001768 | null | 80.7 | Neo-adjuvant (N) | 2016-11-21 | 2016-11-21 | Bexarotene | 02 | null | 310019293 | MITOMYCIN INTRAVESICULAR |
| 310004138 | 310001770 | null | null | Palliative (P) | null | 2016-03-08 | Cisplatin +Fluorouracil (3 wk) | null | Y | 310019303 | BCG |
| 310004139 | 310001771 | 1.6 | 77.7 | null | null | 2017-08-08 | Oxaliplatin + Modified de Gramont | null | null | 310019304 | VEMURAFENIB |
| 310004140 | 310001772 | null | 57.6 | Neo-adjuvant (N) | 2016-02-15 | 2016-02-16 | CISPLATIN + FLUOROURACIL | 02 | null | 310019309 | RITUXIMAB |
| 310004141 | 310006767 | 1.57 | null | Adjuvant (A) | 2017-11-14 | 2017-12-17 | STS Non-Rhabdo EpSSG 2005 Ifos Dox | 2 | N | 310019312 | NOT MATCHED |
| 310004142 | 310006767 | null | 56.6 | Palliative (P) | null | 2016-04-05 | Dacarbazine | 1 | null | 310019312 | GEMCITABINE + PACLITAXEL |
| 310004143 | 310001773 | 1.65 | 83 | Palliative (P) | 2014-11-15 | 2014-12-11 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 310019324 | DACARBAZINE |
| 310004144 | 310001774 | 1.6 | 3.7 | Palliative (P) | 2015-08-13 | 2015-08-30 | IPILIMUMAB + NIVOLUMAB | 02 | N | 310019329 | IPILIMUMAB + NIVOLUMAB |
| 310004145 | 310001775 | 1.79 | 82.6 | Neo-adjuvant (N) | 2014-04-27 | 2014-05-16 | GEMCITABINE | N | N | 310019331 | MITOMYCIN INTRAVESICULAR |
| 310004146 | 310001776 | 1.59 | 96.7 | Palliative (P) | null | 2014-10-26 | IPILIMUMAB + NIVOLUMAB | N | N | 310019332 | IPILIMUMAB + NIVOLUMAB |
| 310004147 | 310001777 | 1.62 | 60.8 | Neo-adjuvant (N) | 2017-10-28 | 2017-11-12 | Imatinib 400mg | 02 | N | 310019333 | CISPLATIN + ETOPOSIDE |
| 310004148 | 310001778 | 1.62 | 85 | Palliative (P) | 2015-03-01 | 2015-03-02 | ECX | 02 | N | 310019334 | ECX |
| 310004149 | 310001779 | 1.84 | 95 | Neo-adjuvant (N) | null | 2016-07-28 | Oxaliplatin + Modified de Gramont | N | N | 310019337 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004150 | 310001780 | 1.62 | 48.7 | Disease modification (D) | 2013-05-10 | 2013-05-12 | Dacarbazine | N | N | 310019339 | HYDROXYCARBAMIDE |
| 310004151 | 310001781 | null | 75.2 | null | 2015-05-28 | 2015-05-28 | Hydroxycarbamide | N | N | 310019343 | CAPECITABINE + OXALIPLATIN |
| 310004152 | 310006768 | null | 117.7 | Adjuvant (A) | 2017-12-25 | 2017-12-29 | CHOEP - 21 days | 02 | N | 310019346 | CHOEP |
| 310004153 | 310001782 | 1.67 | 0 | Palliative (P) | 2015-08-18 | 2015-08-31 | ECX | 02 | N | 310019347 | ECX |
| 310004154 | 310001783 | 1.59 | 60 | Curative (C) | 2015-04-20 | 2015-04-23 | null | N | N | 310019348 | NOT MATCHED |
| 310004155 | 310006769 | null | null | Curative (C) | 2016-10-19 | 2016-10-19 | Cisplatin + Etoposide po&iv 3 day | N | N | 310019349 | CAPECITABINE |
| 310004157 | 310001785 | 1.81 | null | Palliative (P) | 2014-07-07 | 2014-07-15 | Dacarbazine | N | N | 310019351 | LIPOSOMAL DOXORUBICIN |
| 310004158 | 310001786 | 1.73 | 0 | Neo-adjuvant (N) | 2016-05-09 | 2016-05-21 | EOX | null | null | 310019352 | CISPLATIN + FLUOROURACIL |
| 310004159 | 310001786 | 1.75 | 74.1 | Not known (9) | 2016-06-30 | 2016-07-03 | GEMCITABINE | 02 | null | 310019352 | GEMCITABINE |
| 310004160 | 310001787 | 1.52 | 62 | Palliative (P) | 2015-06-19 | 2015-06-26 | IMATINIB | N | N | 310019360 | CISPLATIN + ETOPOSIDE |
| 310004161 | 310001787 | 1.56 | null | Palliative (P) | 2016-04-15 | 2016-04-15 | Capecitabine + Cisplatin | N | N | 310019360 | CAPECITABINE + OXALIPLATIN |
| 310004162 | 310001787 | 1.83 | 62.9 | null | 2017-06-18 | 2017-06-21 | Liposomal Doxorubicin (20mg/m2) | N | null | 310019360 | RITUXIMAB |
| 310004163 | 310001788 | 1.72 | 80 | Neo-adjuvant (N) | 2015-01-24 | 2015-02-04 | ICON8 TRIAL | 02 | N | 310019364 | EOX |
| 310004164 | 310006772 | 1.5 | 48.9 | Curative (C) | 2015-08-09 | 2015-08-11 | NHL IntB NHL ritu 2010 GpC COPADM1R | N | N | 310019366 | NOT MATCHED |
| 310004165 | 310006772 | 1.58 | null | Adjuvant (A) | 2017-08-23 | 2017-09-03 | GEMCITABINE | Y | N | 310019366 | GEMCITABINE |
| 310004166 | 310006772 | 1.6 | 63 | Adjuvant (A) | null | 2013-06-28 | CHOEP - 21 days | N | N | 310019366 | CHOEP |
| 310004167 | 310001789 | 0 | 13 | Disease modification (D) | 2014-11-18 | 2014-11-18 | Hydroxycarbamide | N | N | 310019372 | EOX |
| 310004168 | 310001790 | -1 | 73.35 | Palliative (P) | 2017-08-19 | 2017-08-20 | CHOEP - 21 days | N | N | 310019374 | EOX |
| 310004169 | 310001791 | 1.69 | 81 | Palliative (P) | 2018-03-25 | 2018-03-25 | ECX | N | N | 310019375 | ECX |
| 310004170 | 310001792 | 1.78 | 80.7 | Disease modification (D) | 2016-10-10 | 2016-10-18 | GEM-P | 02 | N | 310019376 | BEXAROTENE |
| 310004171 | 310001793 | 1.61 | 69.7 | Palliative (P) | 2013-09-11 | 2013-09-11 | Cisplatin +Fluorouracil (3 wk) | N | N | 310019380 | CISPLATIN + ETOPOSIDE |
| 310004172 | 310001794 | 1.88 | 75.3 | Neo-adjuvant (N) | 2015-04-27 | 2015-05-02 | ECX | N | N | 310019382 | ECX |
| 310004173 | 310001795 | 1.61 | 83 | null | null | 2013-07-02 | Cisplatin +Fluorouracil (3 wk) | 02 | N | 310019383 | LIPOSOMAL DOXORUBICIN |
| 310004174 | 310006773 | null | null | Palliative (P) | 2016-02-14 | 2016-02-28 | Capecitabine + Cisplatin | N | N | 310019384 | CAPECITABINE + CISPLATIN |
| 310004175 | 310001796 | 1.73 | 75 | Palliative (P) | 2017-06-30 | 2017-07-07 | GEM-P | 02 | N | 310019386 | CISPLATIN + ETOPOSIDE |
| 310004176 | 310001797 | 1.79 | 105.7 | Palliative (P) | 2018-06-11 | 2018-06-12 | Mitomycin Intravesical | 2 | N | 310019387 | BEXAROTENE |
| 310004177 | 310001798 | null | 62 | Neo-adjuvant (N) | 2015-11-04 | 2015-11-16 | Liposomal Doxorubicin 40mg/m2 | 02 | N | 310019388 | BEXAROTENE |
| 310004178 | 310001798 | 1.57 | 58.1 | Curative (C) | 2014-09-11 | 2014-10-19 | Retinoblastoma Rel | null | N | 310019388 | NOT MATCHED |
| 310004179 | 310001798 | 1.82 | 70.1 | Disease modification (D) | 2013-09-27 | 2013-09-28 | Liposomal Doxorubicin (Caelyx) | N | N | 310019388 | VEMURAFENIB |
| 310004180 | 310001799 | 1.57 | 63.8 | Curative (C) | 2014-12-24 | 2015-01-29 | ECX | N | null | 310019393 | ECX |
| 310004181 | 310001800 | 1.78 | 113 | Palliative (P) | 2016-08-01 | 2016-08-20 | Dacarbazine | N | N | 310019394 | VEMURAFENIB |